- Home
- ADTX
ADTX
Aditxt Inc.
as 04-01-2025 4:00pm EST
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 5.3M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 8.2M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -311.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.11 - $54500.00 | Next Earning Date: | 05-19-2025 |
| Revenue: | $133,985 | Revenue Growth: | -71.70% |
| Revenue Growth (this year): | 95.61% | Revenue Growth (next year): | 1584.79% |
Latest Aditxt Inc. News
ADTX Breaking Stock News: Dive into ADTX Ticker-Specific Updates for Smart Investing
Business Wire
5 days ago
Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
PR Newswire
9 days ago
Evofem Reports Fourth Consecutive Year of Net Sales Growth
Business Wire
9 days ago
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
GlobeNewswire
15 days ago
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
Business Wire
16 days ago
Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025
Business Wire
21 days ago
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025
Business Wire
a month ago
Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.
TipRanks
a month ago
Aditxt subsidiary Persanta engages Dominary Securities for IPO
Compare ADTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADTX Aditxt Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.